Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–8.

Article  CAS  PubMed  Google Scholar 

Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489–94.

Article  CAS  PubMed  Google Scholar 

Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res. 2000;887:239–49.

Article  CAS  PubMed  Google Scholar 

Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15:1358–65.

Article  CAS  PubMed  Google Scholar 

Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–42.

Article  CAS  PubMed  Google Scholar 

Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007;7:919–43.

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.

Article  CAS  PubMed  Google Scholar 

Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–53.

Article  CAS  PubMed  Google Scholar 

Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahenk Z, Barohn R, New P, Mendell JR. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol. 1994;51:726–9.

Article  CAS  PubMed  Google Scholar 

Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993;15:107–15.

Google Scholar 

Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer. 1995;31A(Suppl 4):S1-6.

Article  CAS  Google Scholar 

Boer HH, Moorer-van Delft CM, Muller LJ, Kiburg B, Vermorken JB, Heimans JJ. Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. J Neurooncol. 1995;25:49–57.

Article  CAS  PubMed  Google Scholar 

Windebank AJ. The vehicle for cyclosporine is neurotoxic in vitro. Ann Neurol. 1997;41:563–4.

Article  CAS  PubMed  Google Scholar 

Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994;268:1051–6.

CAS  PubMed  Google Scholar 

Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol. 2007;25:5070–7.

Article  PubMed  Google Scholar 

Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res. 1997;6:225–36.

Article  CAS  PubMed  Google Scholar 

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9:739–44.

Article  CAS  PubMed  Google Scholar 

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49.

Article  CAS  PubMed  Google Scholar 

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17:1483–91.

Article  PubMed  Google Scholar 

Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer. 2009;17:1071–80.

Article  PubMed  Google Scholar 

Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized phase III Trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or Ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33:2361–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, et al. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast. 2021;55:63–8.

Article  PubMed  Google Scholar 

Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, et al. Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer. 2015;15:191–6.

Article  CAS  PubMed  Google Scholar 

Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute common toxicity scale. J Peripher Nerv Syst. 2011;16:228–36.

Article  PubMed  Google Scholar 

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479–94.

Article  CAS  PubMed  Google Scholar